XTRA Bitcoin Inc (CBTC)

[Fat Thor]

TCEL BOTTOM LINE PER LAST Q report

A. a description of the issuer’s business operations;
The Company’s business operations consist of doing business in the cell repair and cell replacement for Equine stock
only at present, but we are pursuing FDA approval for existing and modified products to be used for the repair of the
Human Body. Its products have been successfully utilised for the repair of horses tendons and have the added bonus
of being patented worldwide, with an exclusive licence in the name of the Company for equine and human OTC Markets Group Inc.
OTC Pink Basic Disclosure Guidelines (v1.0 January 3, 2013) Page 8 of 11
applications. In October 2013 we had to cease trialing the process due to lack of available and sustainable funds. The
new initiative to generate investment into the company will allow us to recommence these trials and move towards
selling the equine product on the open market. As a result, the Company is still in development and approval stage.
We are looking to raise the estimated $2million required to obtain US Food and Drug Administration approval of the
patented process for humans and to make the product available to our targeted markets. This process has continued
and has found some success following the release into the market of converted stocks. Interest in our shares has
been encouraging with the conversion of a large portion of our long-term debt into Common Stock which has in turn
necessitated our increasing the authorized capital of the Company. Although we are still short of our targetted
investment level which would allow trials to recommence, we will be looking to take advantage of the market activity
by issuing new shares in the near future as well as developing other long-term investment possibilities.